These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8557970)

  • 1. Complications and survival of 315 patients with malignant-phase hypertension.
    Lip GY; Beevers M; Beevers DG
    J Hypertens; 1995 Aug; 13(8):915-24. PubMed ID: 8557970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension.
    Lip GY; Beevers M; Beevers DG
    J Hypertens; 2000 Jan; 18(1):97-101. PubMed ID: 10678549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does renal function improve after diagnosis of malignant phase hypertension?
    Lip GY; Beevers M; Beevers DG
    J Hypertens; 1997 Nov; 15(11):1309-15. PubMed ID: 9383181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hypertension in the elderly.
    Lip GY; Beevers M; Potter JF; Beevers DG
    QJM; 1995 Sep; 88(9):641-7. PubMed ID: 7583078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry.
    Shantsila A; Shantsila E; Beevers DG; Lip GYH
    J Hypertens; 2017 Nov; 35(11):2310-2314. PubMed ID: 28622157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception.
    Lip GY; Beevers M; Beevers DG
    QJM; 1997 Sep; 90(9):571-5. PubMed ID: 9349449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England.
    Lip GY; Beevers M; Beevers G
    J Hypertens; 1994 Nov; 12(11):1297-305. PubMed ID: 7868878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study.
    Shantsila A; Lane DA; Beevers DG; Lip GY
    J Hypertens; 2012 May; 30(5):974-9. PubMed ID: 22495136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project.
    Shantsila A; Lane DA; Beevers DG; Lip GY
    Hypertens Res; 2013 Jun; 36(6):546-9. PubMed ID: 23407241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic disparities in the incidence, presentation and complications of malignant hypertension.
    van den Born BJ; Koopmans RP; Groeneveld JO; van Montfrans GA
    J Hypertens; 2006 Nov; 24(11):2299-304. PubMed ID: 17053554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis.
    Kawazoe N; Eto T; Abe I; Takishita S; Ueno M; Kobayashi K; Uezono K; Muratani H; Kimura Y; Tomita Y
    Clin Nephrol; 1988 Feb; 29(2):53-7. PubMed ID: 3359695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hypertension in patients with idiopathic IgA nephropathy.
    Chen Y; Tang Z; Yang G; Shen S; Yu Y; Zeng C; Chen H; Liu ZH; Li LS
    Kidney Blood Press Res; 2005; 28(4):251-8. PubMed ID: 16340218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in malignant hypertension selected by multivariate analysis.
    Guerin C; Berthoux F
    Nephrol Dial Transplant; 1990; 5(8):563-8. PubMed ID: 23275987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hypertension with lone bilateral papilloedema: a variant of malignant hypertension.
    Lip GY; Beevers M; Dodson PM; Beevers DG
    Blood Press; 1995 Nov; 4(6):339-42. PubMed ID: 8746600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant hypertension--improving prognosis in a rare disease.
    Gudbrandsson T; Hansson L; Herlitz H; Andrén L
    Acta Med Scand; 1979; 206(6):495-9. PubMed ID: 532711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study on the outcome of percutaneous transluminal renal angioplasty in patients with renal failure.
    Roussos L; Christensson A; Thompson O
    Nephron Clin Pract; 2006; 104(3):c132-42. PubMed ID: 16899992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival of malignant hypertension in blacks, whites and Asians in Britain.
    Clough CG; Beevers DG; Beevers M
    J Hum Hypertens; 1990 Apr; 4(2):94-6. PubMed ID: 2338701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective and prospective research on hypertension-related end-organ damage.
    Perloff D
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S1-5. PubMed ID: 7603071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Renal Outcome among Japanese Patients with or without Microangiopathic Hemolysis in Malignant Phase Hypertension: A Single-Center Retrospective Study.
    Nagayama Y; Inoue Y; Inui K; Yoshimura A
    Nephron; 2017; 137(3):197-204. PubMed ID: 28817823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Preston RA; Materson BJ; Reda DJ; Hamburger RJ; Williams DW; Smith MH
    Clin Nephrol; 1997 May; 47(5):310-5. PubMed ID: 9181278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.